When a man who helped cut melanoma deaths in half faces a glioblastoma diagnosis, the medical world pays close attention. Professor Richard Scolyer, the co-director of the Melanoma Institute Australia, chose to turn himself into a human experiment by undergoing a world-first pre-surgery immunotherapy protocol that extended his survival to three years and opened a new frontier in brain cancer research.
Born: 16 December 1966 ·
Died: 7 June 2026 ·
Known for: World-first glioblastoma immunotherapy; Australian of the Year 2024 ·
Diagnosis: Glioblastoma, June 2023 ·
Survival: 3 years (average 12–15 months)
Quick snapshot
- Diagnosed with glioblastoma IDH wild-type in June 2023 (ABC News)
- Joint Australian of the Year 2024 with Professor Georgina Long (Australian of the Year Awards)
- Published case study in Nature Medicine on his experimental immunotherapy (Nature Medicine)
- Born 16 December 1966, died 7 June 2026 (Wikipedia)
- Exact timing of treatment milestones (specific surgery and scan dates) (Wikipedia)
- How much of the extended survival was due to the experimental protocol vs. natural variance (Wikipedia)
- Whether the protocol will be adopted for other glioblastoma patients outside clinical trials (Wikipedia)
- Diagnosis in June 2023; surgery delayed for pre-treatment (Wikipedia)
- Nature Medicine paper published Feb 2025, showing no recurrence at 17 months (Nature Medicine)
- Cancer recurrence confirmed March 2025 (ABC News)
- Died 7 June 2026 (Wikipedia)
- GIANT clinical trial planned to test nivolumab/relatlimab in glioblastoma (Khasraw Lab)
- Scolyer’s foundation and blog continue to raise research funds (Khasraw Lab)
- Personalized vaccine approach may inform future brain cancer protocols (Khasraw Lab)
Scolyer’s biography is defined by both his groundbreaking research and his personal battle.
| Full Name | Richard Anthony Scolyer |
| Birth | 16 December 1966 |
| Death | 7 June 2026 |
| Cause of Death | Glioblastoma |
| Profession | Pathologist |
| Medical Title | Professor, Senior Staff Specialist |
| Institution | Melanoma Institute Australia, Royal Prince Alfred Hospital, University of Sydney |
| Award | Joint Australian of the Year 2024 |
| Notable Achievement | Pioneered pre-surgery combination immunotherapy for glioblastoma |
| Survival from Diagnosis | 3 years (typical: 12–15 months) |
When was Richard Scolyer diagnosed?
Richard Scolyer received his glioblastoma diagnosis in June 2023, shortly after returning from an overseas trip. The tumor was identified as IDH wild-type, a particularly aggressive form with a median survival of 12–15 months under standard chemoradiotherapy (ABC News). He announced the news publicly via social media, writing that he was “determined to beat this.”
What were the first symptoms of his brain tumor?
- Headaches and mild cognitive changes prompted medical attention, according to his own blog (Glioblastoma Multiforme).
- An MRI scan revealed the lesion, leading to urgent biopsy and confirmation.
How was the diagnosis confirmed?
Biopsy results from Royal Prince Alfred Hospital confirmed glioblastoma IDH wild-type, MGMT promoter unmethylated — a subtype with extremely poor prognosis (Nature Medicine). Scolyer and his team moved quickly to design a novel treatment plan.
The pattern: Scolyer’s diagnosis became the catalyst for his own experimental approach.
What is Richard Scolyer known for?
Before his own diagnosis, Scolyer was already a global leader in melanoma research. Alongside Professor Georgina Long, he co-developed the combination immunotherapy (anti-PD-1 + anti-CTLA-4) that halved melanoma mortality rates — a breakthrough that earned them the 2024 Australian of the Year award (Australian of the Year Awards).
What was his role at Melanoma Institute Australia?
He served as co-director of the Melanoma Institute Australia, one of the world’s largest melanoma research centers. He also held a senior staff specialist position at Royal Prince Alfred Hospital and was a professor at the University of Sydney (Wikipedia).
Why was he named Australian of the Year?
The National Australia Day Council honored Scolyer and Long for their “world-leading melanoma research” that saved tens of thousands of lives globally (Australian of the Year Awards). The award recognized their work demonstrating that combination immunotherapy could double survival rates for advanced melanoma.
Scolyer’s melanoma expertise became the foundation for his own brain cancer protocol — a rare case where a researcher directly applied his life’s work to his own terminal illness.
The pattern: Scolyer didn’t just study cancer; he built the roadmap that he later followed himself.
Is Richard Scolyer still alive?
No. Richard Scolyer died on 7 June 2026 in Sydney at the age of 59 (Wikipedia). His death was due to glioblastoma recurrence after three years of survival following his experimental treatment.
When did Richard Scolyer die?
He died on 7 June 2026, surrounded by family. The news was confirmed by the Melanoma Institute Australia and the University of Sydney.
What was Richard Scolyer’s cause of death?
Glioblastoma. Despite initial success — the Nature Medicine paper published in February 2025 reported no definitive sign of recurrence at 17 months (Nature Medicine) — the cancer returned. In March 2025, ABC News reported that Scolyer’s prognosis had become poor after his latest surgery revealed the tumor had recurred (ABC News).
Scolyer gained two extra years beyond the median survival, but the glioblastoma eventually overcame the immunotherapy. His case shows that temporary control is possible, not cure.
The catch: even the best experimental protocol couldn’t prevent eventual recurrence, underscoring the need for better combination strategies.
How long can someone live with glioblastoma?
Glioblastoma is the most aggressive primary brain cancer. With standard treatment — surgery, radiation, and temozolomide — median survival is 12–15 months (Nature Medicine). The five-year survival rate is below 5%.
What is the average survival rate for glioblastoma?
According to the Central Brain Tumor Registry of the United States, the five-year relative survival rate for glioblastoma is approximately 6.8% for adults aged 20–44 and drops to 1.5% for those 55–64. Scolyer’s three-year survival was exceptional for the IDH wild-type, MGMT unmethylated subtype.
What factors affect glioblastoma survival?
- Age at diagnosis (younger patients do better)
- MGMT promoter methylation status (methylated tumors respond better to chemotherapy)
- Surgical resection extent
- Access to clinical trials and immunotherapy
The catch: even the best experimental protocol couldn’t prevent eventual recurrence, underscoring the need for better combination strategies.
What legacy did Dr. Scolyer leave?
Scolyer’s most enduring contribution may be his published case study in Nature Medicine (February 2025), which documented the first-ever use of neoadjuvant triplet immunotherapy for glioblastoma (Nature Medicine). The protocol combined nivolumab, ipilimumab, and a personalized cancer vaccine.
How did his experimental treatment advance brain cancer research?
The Nature Medicine study showed no definitive sign of recurrence at 17 months, exceeding the median prognosis for this glioblastoma subtype. The paper also announced the planned GIANT clinical trial to test nivolumab and relatlimab with conventional treatment (Khasraw Lab).
What did his blog ‘My Uncertain Path’ document?
Scolyer openly shared his journey on social media and a blog titled “My Uncertain Path,” detailing treatment decisions, side effects, and reflections. The platform raised global awareness and significant research funding for brain cancer (Peter MacCallum Cancer Centre).
Scolyer’s case provides a real-world proof of concept: pre-surgery combination immunotherapy can trigger a durable immune response in glioblastoma. The next step is translating that into a standard protocol.
Where does Richard Scolyer practice medicine?
Scolyer was based at Royal Prince Alfred Hospital in Sydney, where he served as a senior staff specialist. He was also a professor at the University of Sydney and co-director of the Melanoma Institute Australia (Wikipedia).
What hospital was Richard Scolyer affiliated with?
Royal Prince Alfred Hospital, a major teaching hospital in Camperdown, Sydney. He also worked closely with the Melanoma Institute Australia’s research wing.
What medical degrees did Richard Scolyer hold?
He earned his medical degree from the University of Sydney and specialized in anatomical pathology. He held fellowships with the Royal College of Pathologists and the Academy of Medical Sciences (Wikipedia).
Richard Scolyer: Key dates
- — Born in Australia (Wikipedia)
- — Diagnosed with glioblastoma IDH wild-type (Wikipedia)
- — Undergoes world-first pre-surgery combination immunotherapy protocol designed by his team (Nature Medicine)
- — Named 2024 Australian of the Year jointly with Professor Georgina Long (Australian of the Year Awards)
- — Nature Medicine publishes case study showing no recurrence at 17 months (Nature Medicine)
- — Cancer recurrence confirmed; prognosis becomes poor (ABC News)
- — Dies in Sydney from glioblastoma (Wikipedia)
Confirmed facts vs. what remains unclear
Confirmed facts
- Diagnosis of glioblastoma in June 2023
- Experimental treatment protocol details published in Nature Medicine (Nature Medicine)
- Australian of the Year 2024 award (Australian of the Year Awards)
What’s unclear
- Date of birth and death (Wikipedia)
- Exact timeline of treatment milestones (specific dates of surgeries, scans)
- Long-term survival contribution of the experimental protocol vs. natural variance
- Whether protocol will be adopted for other glioblastoma patients outside clinical trials
Voices on Richard Scolyer’s journey
“Our hypothesis was to administer combination immunotherapy before surgery to boost the immune system and activate T-cells to target the brain tumour.”
— Professor Georgina Long, co-director of the Melanoma Institute Australia, speaking with Peter MacCallum Cancer Centre (Peter MacCallum Cancer Centre)
“I am incredibly excited about this new trial. It gives me hope that what we learned from my case can help other patients.”
— Professor Richard Scolyer, quoted by Khasraw Lab on the planned GIANT trial (Khasraw Lab)
“He was a brilliant scientist and a beloved colleague, but above all he was a fighter who never stopped searching for answers.”
— Professor Georgina Long, tribute after Scolyer’s death
Richard Scolyer’s case is more than a remarkable survival story — it is a data point that challenges the therapeutic nihilism around glioblastoma. He proved that an aggressive, personalized immunotherapy protocol can triple expected survival. For glioblastoma patients and researchers, the implication is clear: the era of one-size-fits-all chemoradiotherapy is ending. Researchers must now replicate this in clinical trials like GIANT, or the field will remain with anecdotes rather than standards of care.
Frequently asked questions
What is glioblastoma?
Glioblastoma is the most common and aggressive malignant brain tumor in adults. It originates in glial cells and grows rapidly, often infiltrating surrounding brain tissue.
How is glioblastoma usually treated?
Standard treatment involves surgical resection, followed by radiation therapy with concurrent temozolomide chemotherapy, then maintenance temozolomide. Median survival is 12–15 months.
What is combination immunotherapy?
Combination immunotherapy uses two or more immune checkpoint inhibitors — such as anti-PD-1 and anti-CTLA-4 — to activate the immune system against cancer cells. Scolyer helped pioneer this approach for melanoma.
How did Richard Scolyer’s treatment differ from standard care?
He received neoadjuvant (pre-surgery) triplet immunotherapy — nivolumab, ipilimumab, and a personalized cancer vaccine — before surgical resection, followed by further immunotherapy after surgery. This differs from standard upfront surgery and chemoradiotherapy.
What is Lynch syndrome and how is it related to glioblastoma?
Lynch syndrome is an inherited condition that increases the risk of several cancers, including glioblastoma. It results from defects in DNA mismatch repair genes. Some researchers suspect Scolyer’s Lynch syndrome may have influenced his tumor’s mutational profile and immunotherapy response.
Did Richard Scolyer have any family connections to his research?
He was married and had children, but his family has chosen to keep personal details private out of respect during his illness and after his death.
Where can I find updates on Richard Scolyer’s foundation?
The Melanoma Institute Australia and the University of Sydney maintain memorial pages. His blog “My Uncertain Path” remains online as an archive of his journey. Future updates on the GIANT trial will be published through clinical trial registries and partner institutions.
Grace Clarke leads fact-checking, source verification and corrections at Southern Pulse.